Rosetta Genomics relocates CEO, expands U.S. ops

With its first diagnostic products scheduled to launch next year, Israel's Rosetta Genomics has opted to expand its U.S. operations and export CEO Amir Avniel stateside. Rosetta says the move signifies an interest in beefing up its U.S. presence while striking new collaborations and partnerships. Avniel is taking over the work done by Michael French, the president of the U.S. division who is leaving the company.

- see the release
- read the report from Globes

Related Articles:
Rosetta Genomics files $39M IPO registration. Report
Rosetta cuts share price. Report